Physician
Arunavathi T. Sangisetty, M.D., Apmc
Arunavathi T. Sangisetty, M.D., Apmc was paid $5.92M by Medicaid between Jan 2018 and Dec 2024, across 72 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 41% of everything it billed.
33Billing provider infoARUNAVATHI T. SANGISETTY, M.D., APMC
HOUMA, LA 70360
HOUMA, LA 70360
33aNPI1205852746assigned 07/15/2006
33bProvider typePediatrics Physician
28Total paid$5.92M
24GClaims229,467
24DCodes billed72
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Pediatrics Physician providers in Louisiana
Rank by total paid#24 of 230
Median peer was paid$429K
This provider vs. median14×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 33,583 | $894K | |
| 2019 | 37,727 | $944K | |
| 2020 | 27,684 | $950K | |
| 2021 | 29,136 | $862K | |
| 2022 | 29,770 | $847K | |
| 2023 | 32,015 | $759K | |
| 2024incomplete | 39,552 | $661K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 41% | 68,183 | 54,061 | $2.44M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 17% | 16,262 | 14,451 | $979K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 6.5% | 1,139 | 1,088 | $385K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 5.4% | 5,863 | 5,293 | $320K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 5.4% | 5,626 | 5,182 | $317K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 3.1% | 3,687 | 3,359 | $181K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 2.5% | 3,114 | 2,673 | $150K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 2.4% | 12,334 | 11,045 | $145K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 2.3% | 372 | 342 | $134K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.8% | 4,892 | 4,739 | $105K |
| 92551 | 1.6% | 15,496 | 13,757 | $95K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 1.5% | 1,198 | 1,131 | $89K |
60 more codes
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 1.4% | 8,346 | $85K |
| 90472 | Immunization administration, each additional vaccine (list separately) | 1.0% | 7,260 | $60K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 2,047 | $57K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 794 | $54K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,050 | $41K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,049 | $41K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 7,075 | $35K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 3,685 | $33K |
| 99051 | <1% | 3,025 | $32K | |
| 99173 | <1% | 15,947 | $19K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 813 | $16K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 1,092 | $16K |
| 81002 | <1% | 6,671 | $10K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 462 | $10K |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 170 | $9K |
| 81025 | <1% | 2,005 | $8K | |
| 87807 | <1% | 799 | $7K | |
| 99460 | <1% | 167 | $7K | |
| 85018 | <1% | 3,823 | $7K | |
| 83655 | <1% | 655 | $6K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 1,440 | $6K |
| 96127 | <1% | 1,878 | $5K | |
| 99381 | <1% | 139 | $4K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 43 | $2K |
| 94761 | <1% | 2,234 | $2K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,893 | $2K |
| 99050 | <1% | 81 | $866.78 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 83 | $659.88 |
| 96161 | <1% | 155 | $537.24 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,823 | $355.39 |
| 81003 | <1% | 204 | $317.29 | |
| 99384 | <1% | 15 | $270.57 | |
| 90474 | <1% | 25 | $219.12 | |
| 99441 | <1% | 31 | $198.17 | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 46 | $55.00 |
| 94760 | <1% | 35 | $23.73 | |
| 90634 | <1% | 1,857 | $17.77 | |
| 90723 | 0% | 602 | $0.00 | |
| 90619 | 0% | 603 | $0.00 | |
| 90680 | 0% | 753 | $0.00 | |
| 90697 | 0% | 145 | $0.00 | |
| 90696 | 0% | 254 | $0.00 | |
| 90686 | 0% | 518 | $0.00 | |
| 90716 | 0% | 86 | $0.00 | |
| A9150 | Non-prescription drugs | 0% | 29 | $0.00 |
| 90698 | 0% | 26 | $0.00 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 0% | 28 | $0.00 |
| 90648 | 0% | 854 | $0.00 | |
| 90670 | 0% | 1,517 | $0.00 | |
| 90734 | 0% | 1,386 | $0.00 | |
| 90671 | 0% | 289 | $0.00 | |
| 90649 | 0% | 1,189 | $0.00 | |
| 90715 | 0% | 571 | $0.00 | |
| 90473 | 0% | 172 | $0.00 | |
| 90710 | 0% | 327 | $0.00 | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | 0% | 845 | $0.00 |
| 90707 | 0% | 74 | $0.00 | |
| 90658 | 0% | 55 | $0.00 | |
| 90700 | 0% | 45 | $0.00 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSANGISETTY, ARUNA (PRESIDENT)